Clinical trials: Hypercalcemia of Malignancy
Osteoporosis, Humoral Hypercalcemia of Malignancy
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, that can be given safely over one week.
- Conditions
- Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
- Trial name
- NCT00580788
- Testing
- PTHrP (1-36)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Osteoporosis, Hypercalcemia of Malignancy
One Week Comparison Study of PTH and PTHrP Infusions
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers.
- Conditions
- Osteoporosis, Hypercalcemia of Malignancy, Hyperparathyroidism, Bone Diseases, Endocrine
- Trial name
- NCT01333267
- Testing
- Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh